Entresto Generics Loom In India But Wait, Novartis Just Got A Patent

There’s been a significant twist in the Entresto case in India with Novartis securing a patent, but can that put off the launch of generic versions of the blockbuster heart failure therapy later this month?

Patent yellow image
Twist in Entresto Patent Case • Source: Shutterstock

It’s perhaps the biggest twist in the tale to the Entresto (sacubitril/valsartan) patents saga in India and things don’t appear over yet.

Just as several Indian firms appeared to be cruising towards the launch of cut-price versions of Novartis AG’s blockbuster heart failure therapy on the domestic market later this month, the Swiss multinational secured a patent in India (IN414518) pertaining to the

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

A Short History Of MASH Deals, Culminating In GSK/Boston Pharma

 
• By 

Both high-profile failures and small investments that are yielding success so far characterize the dealmaking in MASH over the past 15 years or so.

BioMarin’s $270m Inozyme Buy Fits Right Into Enzyme Therapy Business

 
• By 

BioMarin’s chief business officer James Sabry told Scrip that Inozyme’s enzyme replacement therapy INZ-701 aligns with the company’s existing portfolio and its areas of dealmaking focus.

Regeneron Wins PCSK9 Court Battle Against Amgen

 

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

More from Scrip

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Executives On The Move: Pathos Procures CEO From AstraZeneca, New CEO For TME Pharma, And More

Recent moves in the industry include changes at the top at Akamis Bio, Innospera Pharma & Ispen, plus Astellas Korea appoints an ex-Novartis Korea executive.